Skip to main content Accessibility help
×
Home
Hostname: page-component-5959bf8d4d-2zkqf Total loading time: 1.279 Render date: 2022-12-10T04:50:03.783Z Has data issue: true Feature Flags: { "useRatesEcommerce": false } hasContentIssue true

Plasma carotenoids and diabetic retinopathy

Published online by Cambridge University Press:  13 June 2008

Laima Brazionis*
Affiliation:
Department of Medicine, University of Melbourne (St Vincent's Hospital), Melbourne, VIC 3065, Australia
Kevin Rowley
Affiliation:
Onemda VicHealth Koori Health Unit, Centre for Health and Society, School of Population Health, University of Melbourne, Melbourne, VIC 3010, Australia
Catherine Itsiopoulos
Affiliation:
Department of Medicine, University of Melbourne (St Vincent's Hospital), Melbourne, VIC 3065, Australia
Kerin O'Dea
Affiliation:
Department of Medicine, University of Melbourne (St Vincent's Hospital), Melbourne, VIC 3065, Australia
*
*Corresponding author: Dr Laima Brazionis, fax +61 3 92882581, email laimab@medstv.unimelb.edu.au
Rights & Permissions[Opens in a new window]

Abstract

Diabetic retinopathy increases with duration of diabetes and may be associated with carotenoid status. Carotenoids alter the pro-oxidation/antioxidation balance, and circulating levels depend largely on dietary intake. Lower levels have been reported in diabetes and age-related macular degeneration; however, little is known of the relationship between carotenoids and diabetic complications. Consequently, the purpose of the present study was to evaluate the relationship between plasma carotenoids and diabetic retinopathy. We assessed the carotenoid–retinopathy relationship in 111 individuals with type 2 diabetes in a community-based, cross-sectional study. We photodocumented retinal status and used HPLC to measure plasma carotenoid concentrations. Data for clinical and demographic variables and risk factors for diabetic retinopathy were obtained from 24 h urine and fasting blood samples, and an interviewer-assisted lifestyle questionnaire. We found that the combined lycopene and lutein/zeaxanthin (non-pro-vitamin A (non-PVA) carotenoid) concentration when compared with the pro-vitamin A (PVA) carotenoids (α-carotene, β-carotene and β-cryptoxanthin) was significantly lower in the retinopathy than non-retinopathy group (OR 1·2 (95 % CI 1·0, 1·4) v. 1·6 (95 % CI 1·4, 1·7), respectively; P = 0·009). A higher non-PVA:PVA ratio also predicted a lower risk of diabetic retinopathy, after adjustment for potential confounders (OR 0·33 (95 % CI 0·12, 0·95); P = 0·039). Finally, a higher concentration of PVA carotenoids was associated with greater odds of diabetic retinopathy, after adjustment for risk factors (P = 0·049). We suggest synergies between carotenoids are implicated in diabetic retinopathy, independent of established risk factors. Importantly, our observations indicate dietary modulation of retinopathy risk may be possible by increasing intakes of lutein- and lycopene-rich foods.

Type
Full Papers
Copyright
Copyright © The Authors 2008

Carotenoids demonstrate a vast array of biological activities, including vital roles in the eye, both functionally as precursors to retinol in the visual pathway (pro-vitamin A (PVA) carotenoids) and structurally as macular pigments. The major PVA carotenoids in plasma are α-carotene, β-carotene and β-cryptoxanthin. Of these, only β-carotene is found in ocular tissues(Reference Krinsky and Johnson1).

In contrast, lutein/zeaxanthin and lycopene are the major non-PVA carotenoids, i.e. are not retinol precursors, and both are present in ocular tissues at high concentrations. Lutein and zeaxanthin comprise the macular pigments, essential for normal vision and for the protection of photoreceptors from phototoxic blue light, while lycopene is present in high concentrations in the human ciliary body and retinal pigment epithelium/choroid(Reference Khachik, Carvalho, Bernstein, Muir, Zhao and Katz2).

Plasma carotenoid concentrations have been linked to numerous conditions(Reference Voutilainen, Nurmi, Mursu and Rissanen3Reference Ford, Will, Bowman and Narayan6) including the major blinding conditions – age-related macular degeneration(Reference Cardinault, Abalain, Sairafi, Coudray, Grolier, Rambeau, Carre, Mazur and Rock7, Reference Nilsson, Sundelin, Wihlmark and Brunk8) and cataracts(Reference Gupta, Trivedi, Srivastava, Joshi, Halder and Verma9). To date, the relationship between the major carotenoids and diabetic retinopathy has not been evaluated (Table 1). Consequently, we undertook to investigate the association between plasma carotenoids and diabetic retinopathy.

ND, non-diabetic; T1D, type 1 diabetes; T2D, type 2 diabetes; ACAR, α-carotene; BCAR, β-carotene; BCRY, β-cryptoxanthin; LZ, lutein+zeaxanthin; LYC, lycopene; P, prospective; PVA, pro-vitamin A; T, controlled clinical trial; CC, case–control; H, hospital-based; C, cross-sectional; c, community-based; ESRD, end-stage renal disease; ACR, albumin:creatinine ratio (as indicator of glomerular dysfunction).

* Serum not plasma levels.

Age-adjusted data.

Median values.

Subjects and methods

Diabetes status

Self-reported diabetes status was confirmed biochemically, according to the WHO diagnostic criteria for the classification of diabetes(10).

Subject selection

In order to broaden the range of dietary intakes and lifestyle exposures, we sourced subjects from the Melbourne Collaborative Cohort Study (MCCS), a community-based prospective cohort of 41 528 male and female volunteers, aged 40–69 years at baseline (1989–94), recruited from the electoral roll, and ethnic radio, clubs, and churches(Reference Giles11). We invited 157 men with type 2 diabetes and not taking carotenoid supplements to participate in the present study. Of these, we excluded three (two men with type 1 diabetes and one man with ungradeable photographs). Of the eligible subjects (n 154), 72 % (n 111) participated in the study. Ethics approval was obtained from the MCCS scientific committee and Deakin and Monash Universities (Melbourne, Australia), and written informed consent was obtained from every participant.

Diabetic retinopathy

We used a mydriatic retinal fundus camera (Kowa FX-500S, Japan) to photodocument retinal status. Diabetic retinopathy grading was based on the EURODIAB protocol (validated against the Airlie House classification) in which the overall grading was that of the worse eye and diabetic retinopathy was defined as more than one microaneurysm and/or haemorrhage(Reference Aldington, Kohner, Meuer, Klein and Sjolie12). A medical retina specialist, masked to all other participant information, graded the slides on two separate occasions in order to assess internal validity. Agreement between gradings was excellent (κ value of 0·986).

Clinical measures and retinopathy risk factors

Systolic and diastolic blood pressure was recorded using a Dinamap XL portable automated adult vital signs monitor (model 9300; Critikon, FL, USA). Blood pressure was recorded as the average of the last two of three consecutive readings, obtained from the right arm of seated subjects at 1 min intervals after a 10 min rest period. Weight was measured to within 0·1 kg, using digital electronic scales (UC-300; A.N.D, Tokyo, Japan), before breakfast and following a 12 h fast, with subjects wearing light clothing and no shoes. Height was measured to within 0·1 cm using a wall-mounted stadiometer (Harpenden; Holtain Limited, Crymych, UK). BMI was calculated as weight (kg)/height (m)2. A ‘current smoker’ was defined as a subject who smoked at least seven cigarettes per week at the time of completing the questionnaire.

Plasma biochemistry

A fasting blood sample was drawn between 08.00 and 10.00 hours on the morning of the clinical evaluation. Carotenoids were analysed in plasma separated from blood treated with EDTA as anticoagulant and stored at − 80°C and protected from light until analysed. Extraction was as follows: 200 μl of plasma and 200 μl of 95 % ethanol (containing α-tocopheryl acetate (200 ng/ml) and retinyl acetate (750 ng/ml) as internal standards) were placed in 13 × 100 mm borosilicate tubes (Laboratory Supply, Melbourne, VIC, Australia). Hexane (1 ml) containing 0·01 % butylated hydroxytoluene was added. The different phases were then separated by centrifugation at 2000 g for 10 min. The organic phase was removed by evaporation under N2. The residue was reconstituted in 30 μl chloroform before the addition of 70 μl acetonitrile–methanol (1:1, v/v) and transferred to light-protected vials maintained at 40°C.

A modified HPLC method, developed and reported elsewhere by Su et al. (Reference Su, Rowley and O'Dea13) was used to analyse the prepared samples. Calibration and peak identification for the carotenes were achieved by the use of pure standards obtained from Sigma (St Louis, MO, USA), while calibration and peak identification for lutein/zeaxanthin and β-cryptoxanthin were achieved by the use of pure standards obtained from Hoffman La Roche (Basel, Switzerland). The inter-batch CV was < 10 % for all analytes except lycopene for which the CV was 12 %.

Plasma glucose concentrations were analysed using an automatic analyser (Hitachi model 705, Tokyo, Japan) and a commercial enzymic kit (Boehringer Mannheim GmbH Diagnostica, Mannheim, Germany) by the glucose oxidase method. Plasma cholesterol and TAG concentrations were analysed with an automatic analyser (Hitachi model 705, Tokyo, Japan) using a commercial enzymic kit (Boehringer Mannheim GmbH Diagnostica, Mannheim, Germany).

Urinary biochemistry

Urinary albumin concentration was measured using immunonephelometry (Kallestadt QM300 or Beckman 360 Array nephelometers; inter-assay CV was 3–5 %). Urinary creatinine concentration was measured using an alkaline picrate method (Olympus AU800 autoanalyser; inter-assay CV was 2 %). The urinary albumin:creatinine ratio was then calculated as albumin (mg)/creatinine (mmol).

Statistical analyses

We used SPSS version 13 for Windows (SPSS Inc., Chicago, IL, USA) software to perform the statistical analyses. The data were cross-sectional observations. Descriptive statistics for the exposure and outcome variables were obtained, and variables with distributions that were not normally distributed were log-transformed before analysis. Associations between categorical variables were analysed using χ2 tests.

Initially, variables assessed in univariate analyses, including known risk factors for diabetic retinopathy, were modelled using binomial logistic regression analysis to determine the best clinical predictors of diabetic retinopathy. Plasma carotenoid concentrations were then added to subsequent models that controlled for the major risk factors for diabetic retinopathy. The fit of each model was tested and the Nagelkerke R 2 approximation was compared. P < 0·05 was considered statistically significant.

Results

The mean age of the participants was 64 (range 44–77) years. The clinical and demographic characteristics of the participants, according to retinopathy status, are shown in Table 2. Diabetic retinopathy was significantly associated with established risk factors, i.e. duration of diabetes, HbA1c, use of hypoglycaemic medication, and the albumin excretion rate. A longer duration of diabetes was, however, the only independent predictor of diabetic retinopathy, as demonstrated by multivariate modelling of these factors (data not shown). Mean plasma cholesterol and TAG concentrations were in the normal range and not significantly different between retinopathy and non-retinopathy cases. Consequently, subsequent analyses were not adjusted for cholesterol and TAG concentrations.

Table 2 Characteristics of diabetic subjects according to retinopathy status (Prevalence rates or mean values and 95 % confidence intervals)

* Pearson χ2P values.

The observed mean concentration of each carotenoid for both retinopathy and non-retinopathy cases was within the range of means reported in other diabetic populations (Table 1). The observed α-carotene concentrations were at the higher end of values reported in other diabetic populations and were associated with diabetic retinopathy. Conversely, lycopene, a non-PVA carotenoid, demonstrated a trend to lower levels in the retinopathy group (Table 2). In addition, a higher plasma non-PVA:PVA carotenoid ratio was inversely associated with diabetic retinopathy (1·6 (95 % CI 1·4, 1·7) v. 1·2 (95 % CI 1·0, 1·4), respectively; P = 0·009).

In multivariate modelling of carotenoids as predictors of diabetic retinopathy (Table 3), the odds of diabetic retinopathy increased with higher plasma concentrations of the PVA carotenoids (model 1). The ratio of non-PVA:PVA carotenoid concentrations was the best carotenoid-related predictor of diabetic retinopathy. A higher combined plasma concentration of lycopene and lutein/zeaxanthin was associated with significantly lower odds of diabetic retinopathy, after adjusting for potential confounding by retinopathy risk factors (model 2).

Table 3 Adjusted regression models of plasma carotenoids (μmol/l) as predictors of diabetic retinopathy*

PVA, pro-vitamin A carotenoids (α-+β-carotene+cryptoxanthin); non-PVA, non-pro-vitamin A carotenoids (lutein/zeaxanthin+lycopene).

* Carotenoid and albumin excretion rate data are log-transformed.

Discussion

To date, little is known of the role of carotenoids in diabetes and its complications. Consequently, costly intervention studies of the potential impact of carotenoids on diabetic retinopathy are not yet justifiable, despite evidence of a biologically plausible mechanism, oxidative stress. The present cross-sectional study evaluated the association between diabetic retinopathy and the concentrations of major plasma carotenoids, which in turn are largely, but not exclusively, dependent on dietary intake(Reference Coyne, Ibiebele, McNaughton, Rutishauser, O'Dea, Hodge, McClintock, Findlay and Lee14). Our key finding supports a protective role for a higher combined lutein/zeaxanthin and lycopene concentration against diabetic retinopathy, after adjustment for potential confounders. There are important distinctions between lutein/zeaxanthin and lycopene (non-PVA carotenoids) and the other three major (PVA) carotenoids in humans. Lutein/zeaxanthin and lycopene are absorbed intact, unlike α- and β-carotene and β-cryptoxanthin, which can be cleaved to form retinol and, before absorption, are partly metabolised to vitamin A in the intestinal mucosa(Reference Parker15). Whether competitive inhibition influences PVA carotenoid cleavage at particular intake levels is not well understood. Furthermore, β-carotene is ubiquitous and food sources of various carotenoid combinations differ: lycopene and β-carotene, but not α-carotene, are present in tomatoes, while carrots and pumpkin are good sources of α-carotene and β-carotene, but not lycopene, and cryptoxanthin is primarily found in citrus fruits.

Apart from the key structural role of lutein and zeaxanthin as the macular pigments in the eye, evidence is emerging of a wider role for lutein in chronic disease prevention(Reference Ribaya-Mercado and Blumberg16). In particular, lutein has been shown to attenuate oxidative stress in experimental models of early diabetic retinopathy(Reference Muriach, Bosch-Morell, Alexander, Blomhoff, Barcia, Arnal, Almansa, Romero and Miranda17, Reference Miranda, Muriach, Roma, Bosch-Morell, Genoves, Barcia, Araiz, Diaz-Llospis and Romero18). A role for lycopene in ocular health is also plausible; lycopene is present in high concentrations in human ocular tissues(Reference Khachik, de Moura, Zhao, Aebischer and Bernstein19), is the most potent carotenoid quencher of singlet oxygen(Reference Cantrell, McGarvey, Truscott, Rancan and Bohm20), and has other important functions. In vitro studies have shown that lycopene can inhibit proliferation and induce differentiation of human blood cells, activate genes involved in cell-to-cell communication, and modulate lipoxygenase activity and therefore inflammation and immune function(Reference Heber and Lu21). According to in vitro studies and animal research(Reference Gupta, Trivedi, Srivastava, Joshi, Halder and Verma9), lycopene can attenuate oxidative stress-induced experimental cataract in rat lenses via an antioxidant mechanism involving restoration of levels of endogenous antioxidant enzymes, such as superoxide dismutase and catalase. In one study, lycopene-treated diabetic rabbits demonstrated an increase in antioxidant activity in ocular capillaries and lacrimal fluid(Reference Chesnokova, Grigor'ev, Kuznetsova, Davydova, Olfer'ev, Kost, Nikol'skaia and apitanov22). Low plasma lycopene concentrations have been associated with the very early stages of vascular disease in humans(Reference Rissanen, Voutilainen, Nyyssonen, Salonen, Kaplan and Salonen23), indicating that lycopene contributes to the expression of the disease. Furthermore, lycopene bioavailability is impaired in older individuals(Reference Cardinault, Abalain, Sairafi, Coudray, Grolier, Rambeau, Carre, Mazur and Rock7). In contrast, β-carotene bioavailability is maintained with age, as is the intestinal conversion of PVA carotenoids to vitamin A. Recently, a double-blind placebo-controlled clinical trial found a physiological dose of lycopene for 2 months suppressed oxidative stress and enhanced innate immunity in individuals with type 2 diabetes(Reference Neyestani, Shariatzadeh, Gharavi, Kalayi and Khalaji24).

We also observed an association between retinopathy and plasma PVA carotenoid concentrations. This finding is consistent with one study in which individuals with type 1 diabetes had higher plasma concentrations of PVA (but not non-PVA) carotenoids and lower levels of retinol than their first-degree relatives(Reference Granado, Olmedilla, Gil-Martinez, Blanco, Millan and Rojas-Hidalgo25), suggesting impaired bioconversion of carotenoids to retinol. Diabetes may also promote higher levels of PVA carotenoids via another mechanism, such as down-regulation of the bioconversion of PVA carotenoids to retinol, secondary to a nephropathy-induced accumulation of retinol, levels of which are homeostatically controlled(Reference Gerster26, Reference Thurnham and Northrop-Clewes27) and can be higher in renal disease(Reference Piscator28, Reference Siegenthaler29) and diabetes(Reference Basu and Basualdo30). Importantly, our observation does not demonstrate a negative role of dietary PVA carotenoids. Prospective studies are needed to further evaluate the association between retinopathy and plasma PVA carotenoid concentrations.

Different food sources and intake levels may in part explain the large variation in the ratio of circulating α-carotene: β-carotene reported in previous studies (Table 1). In addition, previous studies point to a complex interplay between carotenoids: non-PVA carotenoids (lutein/zeaxanthin and lycopene) can diminish PVA carotenoid bioavailability. Moreover, synergies have been demonstrated between non-PVA carotenoids(Reference Tyssandier, Choubert, Grolier and Borel31), and competitive inhibition has been demonstrated between carotenoids, for example, for incorporation into chylomicrons(Reference During, Dawson and Harrison32Reference Van het Hof, West, Weststrate and Hautvast34). It is also noteworthy that while carotenoid levels reflect relatively recent intake, evidence suggests that most individuals maintain relatively consistent eating patterns over time, with seasonal fluctuations affecting only cryptoxanthin and β-carotene levels(Reference Granado-Lorencio, Olmedilla-Alonso, Blanco-Navarro, Botella-Romero and Simal-Antón35).

The main limitation of the present study is its observational nature. The lack of temporal direction prevents us from inferring causality. Consequently, prospective studies of diabetic retinopathy are needed to determine whether over time a higher combined plasma concentration of lutein/zeaxanthin and lycopene and/or a higher plasma non-PVA:PVA carotenoid ratio can reduce the risk of diabetic retinopathy. Residual confounding may have played a role in our observations, although sex, a key determinant of plasma carotenoid levels, was not a confounder in the present study as we selected only men with type 2 diabetes. However, the interaction between different food components may have confounded the present results. Furthermore, plasma carotenoids may be a marker for any of the many non-nutrient food components in vegetables and fruits(Reference Watanabe, Zhuo and Kimira36). Finally, although we used a validated protocol for retinal evaluation, our assessment of retinopathy may have underestimated diabetic maculopathy.

In conclusion, synergies between plasma carotenoids seem to be implicated in diabetic retinopathy, independent of established risk factors. In general, the present study provides additional data concerning the importance of carotenoid-rich foods for health maintenance and gives strength to the recommendation of increasing consumption of lutein- and lycopene-rich foods.

Acknowledgements

The present study would not have been possible without the MCCS and the infrastructure support provided by the Cancer Council Victoria. The National Health and Medical Research Council of Australia part-funded the present study (project no. 124317), which represents the collaboration of and contribution by many.

L. B. contributed to the design, data collection, data analyses, and the writing and revision of the manuscript. K. R. contributed to the design, data collection, and revision of the manuscript. C. I. contributed to the design, data collection, data analyses, and revision of the manuscript. K. O'D. contributed to the design and revision of the manuscript. No conflicts of interest exist.

References

1Krinsky, NI & Johnson, EJ (2005) Carotenoid actions and their relation to health and disease. Mol Aspects Med 26, 459516.CrossRefGoogle ScholarPubMed
2Khachik, F, Carvalho, L, Bernstein, PS, Muir, GJ, Zhao, DY & Katz, NB (2002) Chemistry, distribution, and metabolism of tomato carotenoids and their impact on human health. Exp Biol Med (Maywood) 227, 845851.CrossRefGoogle ScholarPubMed
3Voutilainen, S, Nurmi, T, Mursu, J & Rissanen, TH (2006) Carotenoids and cardiovascular health. Am J Clin Nutr 83, 12651271.CrossRefGoogle ScholarPubMed
4Ito, Y, Kurata, M, Hioki, R, Suzuki, K, Ochiai, J & Aoki, K (2005) Cancer mortality and serum levels of carotenoids, retinol, and tocopherol: a population-based follow-up study of inhabitants of a rural area of Japan. Asian Pac J Cancer Prev 6, 1015.Google ScholarPubMed
5Coyne, T, Ibiebele, TI, Baade, PD, Dobson, A, McClintock, C, Dunn, S, Leonard, D & Shaw, J (2005) Diabetes mellitus and serum carotenoids: findings of a population-based study in Queensland, Australia. Am J Clin Nutr 82, 685693.CrossRefGoogle ScholarPubMed
6Ford, ES, Will, JC, Bowman, BA & Narayan, KM (1999) Diabetes mellitus and serum carotenoids: findings from the Third National Health and Nutrition Examination Survey. Am J Epidemiol 149, 168176.CrossRefGoogle ScholarPubMed
7Cardinault, N, Abalain, JH, Sairafi, B, Coudray, C, Grolier, P, Rambeau, M, Carre, JL, Mazur, A & Rock, E (2005) Lycopene but not lutein nor zeaxanthin decreases in serum and lipoproteins in age-related macular degeneration patients. Clin Chim Acta 357, 3442.CrossRefGoogle Scholar
8Nilsson, SE, Sundelin, SP, Wihlmark, U & Brunk, UT (2003) Aging of cultured retinal pigment epithelial cells: oxidative reactions, lipofuscin formation and blue light damage. Doc Ophthalmol 106, 1316.CrossRefGoogle ScholarPubMed
9Gupta, SK, Trivedi, D, Srivastava, S, Joshi, S, Halder, N & Verma, SD (2003) Lycopene attenuates oxidative stress induced experimental cataract development: an in vitro and in vivo study. Nutrition 19, 794799.CrossRefGoogle ScholarPubMed
10World Health Organization (1999) World Health Organization: Diabetes Mellitus: Report of a WHO Study Group. Geneva: WHO.Google Scholar
11Giles, G (1990) The Melbourne study of diet and cancer. Proc Nutr Soc Aust 15, 6168.Google Scholar
12Aldington, SJ, Kohner, EM, Meuer, S, Klein, R & Sjolie, AK (1995) Methodology for retinal photography and assessment of diabetic retinopathy: the EURODIAB IDDM complications study. Diabetologia 38, 437444.CrossRefGoogle ScholarPubMed
13Su, Q, Rowley, K & O'Dea, K (1999) Stability of individual carotenoids, retinol and tocopherols in human plasma during exposure to light and after extraction. J Chromatogr B Biomed Sci Appl 729, 191198.CrossRefGoogle Scholar
14Coyne, T, Ibiebele, TI, McNaughton, S, Rutishauser, IH, O'Dea, K, Hodge, AM, McClintock, C, Findlay, MG & Lee, A (2005) Evaluation of brief dietary questions to estimate vegetable and fruit consumption – using serum carotenoids and red-cell folate. Public Health Nutr 8, 298308.CrossRefGoogle ScholarPubMed
15Parker, RS (1997) Bioavailability of carotenoids. Eur J Clin Nutr 51, Suppl. 1, S86S90.Google ScholarPubMed
16Ribaya-Mercado, JD & Blumberg, JB (2004) Lutein and zeaxanthin and their potential roles in disease prevention. J Am Coll Nutr 23, Suppl. 6, 567S587S.CrossRefGoogle ScholarPubMed
17Muriach, M, Bosch-Morell, F, Alexander, G, Blomhoff, R, Barcia, J, Arnal, E, Almansa, I, Romero, FJ & Miranda, M (2006) Lutein effect on retina and hippocampus of diabetic mice. Free Radic Biol Med 41, 979984.CrossRefGoogle ScholarPubMed
18Miranda, M, Muriach, M, Roma, J, Bosch-Morell, F, Genoves, JM, Barcia, J, Araiz, J, Diaz-Llospis, M & Romero, FJ (2006) Oxidative stress in a model of experimental diabetic retinopathy: the utility of peroxinytrite scavengers (article in Spanish). Arch Soc Esp Oftalmol 81, 2732.Google Scholar
19Khachik, F, de Moura, FF, Zhao, DY, Aebischer, CP & Bernstein, PS (2002) Transformations of selected carotenoids in plasma, liver, and ocular tissues of humans and in nonprimate animal models. Invest Ophthalmol Vis Sci 43, 33833392.Google ScholarPubMed
20Cantrell, A, McGarvey, DJ, Truscott, TG, Rancan, F & Bohm, F (2003) Singlet oxygen quenching by dietary carotenoids in a model membrane environment. Arch Biochem Biophys 412, 4754.CrossRefGoogle Scholar
21Heber, D & Lu, QY (2002) Overview of mechanisms of action of lycopene. Exp Biol Med (Maywood) 227, 920923.CrossRefGoogle ScholarPubMed
22Chesnokova, NB, Grigor'ev, AV, Kuznetsova, TP, Davydova, NG, Olfer'ev, AM, Kost, OA, Nikol'skaia, K II & apitanov, AB (2000) Experimental validation of licopin-containing drug tomatol use in combined therapy of patients with diabetic retinopathy (article in Russian). Vestn Oftalmol 116, 3134.Google Scholar
23Rissanen, TH, Voutilainen, S, Nyyssonen, K, Salonen, R, Kaplan, GA & Salonen, JT (2003) Serum lycopene concentrations and carotid atherosclerosis: the Kuopio Ischaemic Heart Disease Risk Factor Study. Am J Clin Nutr 77, 133138.CrossRefGoogle ScholarPubMed
24Neyestani, TR, Shariatzadeh, N, Gharavi, A, Kalayi, A & Khalaji, N (2007) Physiological dose of lycopene suppressed oxidative stress and enhanced serum levels of immunoglobulin M in patients with type 2 diabetes mellitus: a possible role in the prevention of long-term complications. J Endocrinol Invest 30, 833838.CrossRefGoogle ScholarPubMed
25Granado, F, Olmedilla, B, Gil-Martinez, E, Blanco, I, Millan, I & Rojas-Hidalgo, E (1998) Carotenoids, retinol and tocopherols in patients with insulin-dependent diabetes mellitus and their immediate relatives. Clin Sci (Lond) 94, 189195.CrossRefGoogle ScholarPubMed
26Gerster, H (1997) Vitamin A – functions, dietary requirements and safety in humans. Int J Vitam Nutr Res 67, 7190.Google ScholarPubMed
27Thurnham, DI & Northrop-Clewes, CA (1999) Optimal nutrition: vitamin A and the carotenoids. Proc Nutr Soc 58, 449457.CrossRefGoogle ScholarPubMed
28Piscator, M (1991) Early detection of tubular dysfunction. Kidney Int Suppl 34, S15S17.Google ScholarPubMed
29Siegenthaler, G (1996) Extra-and intracellular transport of retinoids: a reappraisal. Horm Res 45, 122127.CrossRefGoogle ScholarPubMed
30Basu, TK & Basualdo, C (1997) Vitamin A homeostasis and diabetes mellitus. Nutrition 13, 804806.CrossRefGoogle ScholarPubMed
31Tyssandier, V, Choubert, G, Grolier, P & Borel, P (2002) Carotenoids, mostly the xanthophylls, exchange between plasma lipoproteins. Int J Vitam Nutr Res 72, 300308.CrossRefGoogle ScholarPubMed
32During, A, Dawson, HD & Harrison, EH (2005) Carotenoid transport is decreased and expression of the lipid transporters SR-BI, NPC1L1, and ABCA1 is downregulated in Caco-2 cells treated with ezetimibe. J Nutr 135, 23052312.CrossRefGoogle ScholarPubMed
33During, A, Hussain, MM, Morel, DW & Harrison, EH (2002) Carotenoid uptake and secretion by CaCo-2 cells: β-carotene isomer selectivity and carotenoid interactions. J Lipid Res 43, 10861095.CrossRefGoogle ScholarPubMed
34Van het Hof, KH, West, CE, Weststrate, JA & Hautvast, JGAJ (2000) Dietary factors that affect the bioavailability of carotenoids. J Nutr 130, 503506.CrossRefGoogle ScholarPubMed
35Granado-Lorencio, F, Olmedilla-Alonso, B, Blanco-Navarro, I, Botella-Romero, F & Simal-Antón, A (2006) Assessment of carotenoid status and the relation to glycaemic control in type I diabetics: a follow-up study. Eur J Clin Nutr 60, 10001008.CrossRefGoogle ScholarPubMed
36Watanabe, S, Zhuo, XG & Kimira, M (2004) Food safety and epidemiology: new database of functional food factors. Biofactors 22, 213219.CrossRefGoogle ScholarPubMed
37Wang, L, Liu, S, Pradhan, AD, Manson, JE, Buring, JE, Gaziano, JM & Sesso, HD (2006) Plasma lycopene, other carotenoids, and the risk of type 2 diabetes in women. Am J Epidemiol 164, 576585.CrossRefGoogle ScholarPubMed
38Hozawa, A, Jacobs, DR Jr, Steffes, MW, Gross, MD, Steffen, LM & Lee, DH (2006) Associations of serum carotenoid concentrations with the development of diabetes and with insulin concentration: interaction with smoking: the Coronary Artery Risk Development in Young Adults (CARDIA) Study. Am J Epidemiol 163, 929937.CrossRefGoogle ScholarPubMed
39Quilliot, D, Walters, E, Bonte, JP, Fruchart, JC, Duriez, P & Ziegler, O (2005) Diabetes mellitus worsens antioxidant status in patients with chronic pancreatitis. Am J Clin Nutr 81, 11171125.CrossRefGoogle ScholarPubMed
40Sugiura, M, Nakamura, M, Ikoma, Y, Yano, M, Ogawa, K, Matsumoto, H, Kato, M, Ohshima, M & Nagao, A (2006) The homeostasis model assessment-insulin resistance index is inversely associated with serum carotenoids in non-diabetic subjects. J Epidemiol 16, 7178.CrossRefGoogle ScholarPubMed
41Granado, F, Olmedilla, B & Blanco, I (2004) Carotenoid depletion in serum of young type-1 diabetics fed low-carotenoid diets. Ann Nutr Metab 48, 251258.CrossRefGoogle ScholarPubMed
42Ylonen, K, Alfthan, G, Groop, L, Saloranta, C, Aro, A & Virtanen, SM (2003) Dietary intakes and plasma concentrations of carotenoids and tocopherols in relation to glucose metabolism in subjects at high risk of type 2 diabetes: the Botnia Dietary Study. Am J Clin Nutr 77, 14341441.CrossRefGoogle ScholarPubMed
43Suzuki, K, Ito, Y, Nakamura, S, Ochiai, J & Aoki, K (2002) Relationship between serum carotenoids and hyperglycemia: a population-based cross-sectional study. J Epidemiol 12, 357366.CrossRefGoogle ScholarPubMed
44Upritchard, JE, Sutherland, WH & Mann, JI (2000) Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care 23, 733738.CrossRefGoogle ScholarPubMed
45Polidori, MC, Mecocci, P, Stahl, W, Parente, B, Cecchetti, R, Cherubini, A, Cao, P, Sies, H & Senin, U (2000) Plasma levels of lipophilic antioxidants in very old patients with type 2 diabetes. Diabetes Metab Res Rev 16, 1519.3.0.CO;2-B>CrossRefGoogle ScholarPubMed
46Facchini, FS, Humphreys, MH, DoNascimento, CA, Abbasi, F & Reaven, GM (2000) Relation between insulin resistance and plasma concentrations of lipid hydroperoxides, carotenoids, and tocopherols. Am J Clin Nutr 72, 776779.CrossRefGoogle ScholarPubMed
47Levy, Y, Zaltsberg, H, Ben-Amotz, A, Kanter, Y & Aviram, M (2000) Dietary supplementation of a natural isomer mixture of β-carotene inhibits oxidation of LDL derived from patients with diabetes mellitus. Ann Nutr Metab 44, 5460.CrossRefGoogle ScholarPubMed
48Abahusain, MA, Wright, J, Dickerson, JW & de Vol, EB (1999) Retinol, α-tocopherol and carotenoids in diabetes. Eur J Clin Nutr 53, 630635.CrossRefGoogle ScholarPubMed
49Anderson, JW, Gowri, MS, Turner, J, Nichols, L, Diwadkar, VA, Chow, CK & Oeltgen, PR (1999) Antioxidant supplementation effects on low-density lipoprotein oxidation for individuals with type 2 diabetes mellitus. J Am Coll Nutr 18, 451461.CrossRefGoogle ScholarPubMed
50Reunanen, A, Knekt, P, Aaran, RK & Aromaa, A (1998) Serum antioxidants and risk of non-insulin dependent diabetes mellitus. Eur J Clin Nutr 52, 8993.CrossRefGoogle ScholarPubMed
51Olmedilla, B, Granado, F, Gil-Martinez, E, Blanco, I & Rojas-Hidalgo, E (1997) Reference values for retinol, tocopherol, and main carotenoids in serum of control and insulin-dependent diabetic Spanish subjects. Clin Chem 43, 10661071.Google ScholarPubMed
52Krill, D, O'Leary, L, Koehler, AN, Kramer, MK, Warty, V, Wagner, MA & Dorman, JS (1997) Association of retinol binding protein in multiple-case families with insulin-dependent diabetes. Hum Biol 69, 8996.Google ScholarPubMed
53Rock, CL, Jahnke, MG, Gorenflo, DW, Swartz, RD & Messana, JM (1997) Racial group differences in plasma concentrations of antioxidant vitamins and carotenoids in hemodialysis patients. Am J Clin Nutr 65, 844850.CrossRefGoogle ScholarPubMed
54O'Brien, SF, Watts, GF, Powrie, JK, Shaw, KM & Miller, NJ (1996) Lipids, lipoproteins, antioxidants and glomerular and tubular dysfunction in type 1 diabetes. Diabetes Res Clin Pract 32, 8190.CrossRefGoogle ScholarPubMed
Figure 0

Table 1 Diabetes-related studies of plasma concentrations of major carotenoids(5,6,24,25,35,3754)

Figure 1

Table 2 Characteristics of diabetic subjects according to retinopathy status (Prevalence rates or mean values and 95 % confidence intervals)

Figure 2

Table 3 Adjusted regression models of plasma carotenoids (μmol/l) as predictors of diabetic retinopathy*

You have Access
67
Cited by

Save article to Kindle

To save this article to your Kindle, first ensure coreplatform@cambridge.org is added to your Approved Personal Document E-mail List under your Personal Document Settings on the Manage Your Content and Devices page of your Amazon account. Then enter the ‘name’ part of your Kindle email address below. Find out more about saving to your Kindle.

Note you can select to save to either the @free.kindle.com or @kindle.com variations. ‘@free.kindle.com’ emails are free but can only be saved to your device when it is connected to wi-fi. ‘@kindle.com’ emails can be delivered even when you are not connected to wi-fi, but note that service fees apply.

Find out more about the Kindle Personal Document Service.

Plasma carotenoids and diabetic retinopathy
Available formats
×

Save article to Dropbox

To save this article to your Dropbox account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Dropbox account. Find out more about saving content to Dropbox.

Plasma carotenoids and diabetic retinopathy
Available formats
×

Save article to Google Drive

To save this article to your Google Drive account, please select one or more formats and confirm that you agree to abide by our usage policies. If this is the first time you used this feature, you will be asked to authorise Cambridge Core to connect with your Google Drive account. Find out more about saving content to Google Drive.

Plasma carotenoids and diabetic retinopathy
Available formats
×
×

Reply to: Submit a response

Please enter your response.

Your details

Please enter a valid email address.

Conflicting interests

Do you have any conflicting interests? *